Login to Your Account



Theravance Gets Telavancin Partner In Deal Worth $221M

By Karen Pihl-Carey


Wednesday, November 9, 2005
With two Phase III programs ongoing for telavancin, Theravance Inc. found the antibiotic a global partner in Astellas Pharma Inc. through a deal worth up to $221 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription